Chapter review

Fitzgerald PMHNP board review. ch02. Select Special Topics in Psychiatric-Mental Health Practice. This is drive 15 of 18. When I say Pause. Answer. wait, then I will give the answer. New section. Printed Fitzgerald Sample Question. Topic. Question 1 (Fitzgerald Sample Item). A 34-year-old male with a history of schizophrenia is brought to the clinic by his family for follow-up. He has had three psychiatric hospitalizations over the past two years due to stopping his oral antipsychotic medication whenever his symptoms temporarily improve. He expresses a desire to stay out of the hospital and maintain his job. What is the most appropriate medication strategy to prevent future illness relapse? - A. Increase the dose of his current oral antipsychotic. - B. Transition the patient to a long-acting injectable (LAI) antipsychotic. - C. Prescribe daily oral **lorazepam** to reduce medication anxiety. - D. Switch the patient to oral **clozapine** monotherapy. Pause. Answer. B. Why it is correct: Nonadherence to oral antipsychotics is the leading cause of relapse and rehospitalization in **schizophrenia**. Transitioning to a long-acting injectable (LAI) antipsychotic ensures consistent medication delivery, eliminates daily pill-taking demands, and significantly lowers relapse rates. Why each distractor fails: - A. Increasing the dose of an oral medication does not solve the underlying issue of medication nonadherence. - C. Benzodiazepines like **lorazepam** do not treat core psychotic symptoms or prevent illness relapse, and carry risks of dependence. - D. **Clozapine** is reserved for treatment-resistant schizophrenia after two failed antipsychotic trials, not straightforward nonadherence that can be managed with an LAI. Test-taking pearl: Repeated relapses caused by oral nonadherence dictate transitioning to a long-acting injectable (LAI) antipsychotic. Concept tested: Clinical indication for long-acting injectable antipsychotics. Live Board Practice Items. Question 2. A PMHNP is initiating **risperidone microspheres** (**Risperdal Consta**) 25 mg IM every 2 weeks for a 28-year-old female with **schizophrenia** who has a history of poor oral adherence. What critical instructions regarding medication administration must the PMHNP implement during initiation? - A. Require 3 hours of mandatory post-injection clinical observation after each dose. - B. Continue oral **risperidone** co-administration for 3 to 4 weeks following the first injection. - C. Administer a second loading injection in the opposite deltoid muscle on Day 8 without oral coverage. - D. Check absolute neutrophil counts weekly for the first six months. Pause. Answer. B. Why it is correct: **Risperidone microspheres** (**Risperdal Consta**) exhibit a delayed release profile, taking approximately 3 to 4 weeks to produce therapeutic plasma levels. Co-administration of oral **risperidone** during this 3-to-4-week crossover period is essential to prevent psychotic relapse. Why each distractor fails: - A. Mandatory 3-hour post-injection observation is required for **olanzapine pamoate** (**Zyprexa Relprevv**), not **Risperdal Consta**. - C. Day 1 and Day 8 deltoid loading injections without oral overlap is the initiation protocol for **paliperidone palmitate** (**Invega Sustenna**). - D. Weekly ANC monitoring is required for **clozapine**, not **risperidone**. Test-taking pearl: **Risperdal Consta** requires 3 to 4 weeks of oral overlap due to delayed microsphere release. Concept tested: Initiation and oral overlap rules for **Risperdal Consta**. Question 3. A 31-year-old male with **schizophrenia** receives an IM injection of **olanzapine pamoate** (**Zyprexa Relprevv**) at an outpatient clinic. Two hours after the injection, he becomes disoriented, excessively somnolent, slurs his speech, and exhibits an unsteady gait. Vital signs reveal a blood pressure of 102/62 mm Hg and heart rate of 112 beats per minute. What is the PMHNP's priority interpretation and action? - A. Recognize neuroleptic malignant syndrome and administer **dantrolene**. - B. Identify **post-injection delirium sedation syndrome (PDSS)** and immediately arrange emergency medical transfer. - C. Reassure the patient that transient orthostatic hypotension is expected and discharge home. - D. Administer **benztropine** 2 mg IM for acute extrapyramidal ataxia. Pause. Answer. B. Why it is correct: The patient is exhibiting classic signs of **post-injection delirium sedation syndrome (PDSS)** (sedation, confusion, dysarthria, ataxia) caused by accidental intravascular entry of **olanzapine pamoate**. PDSS is a medical emergency requiring immediate emergency medical transfer and evaluation. Why each distractor fails: - A. Neuroleptic malignant syndrome presents with severe lead-pipe rigidity, hyperthermia, and extreme autonomic instability, not isolated post-injection sedation and confusion. - C. Discharging a patient experiencing PDSS is life-threatening; symptoms can progress to unconsciousness and respiratory depression. - D. **Benztropine** treats acute dystonia and parkinsonism, not intravascular olanzapine toxicity. Test-taking pearl: Sudden confusion, slurred speech, and severe sedation within 3 hours of a **Zyprexa Relprevv** injection indicate **PDSS**. Concept tested: Management of post-injection delirium sedation syndrome. Question 4. A PMHNP is planning to initiate **paliperidone palmitate** (**Invega Sustenna**) for a 22-year-old male with a first episode of **schizophrenia** who was successfully stabilized on oral **risperidone**. What is the recommended dosing schedule for initiating **Invega Sustenna**? - A. 150 mg IM in the deltoid on Day 1, followed by 100 mg IM in the deltoid on Day 8, with no oral overlap. - B. 75 mg IM in the gluteal muscle once monthly with 14 days of oral **risperidone** overlap. - C. 273 mg IM in the deltoid every 3 months starting immediately. - D. 50 mg IM in the gluteal muscle every 2 weeks with 4 weeks of oral overlap. Pause. Answer. A. Why it is correct: **Invega Sustenna** is initiated with two deltoid loading doses: 150 mg on Day 1 and 100 mg on Day 8. Deltoid administration achieves rapid therapeutic concentrations, eliminating the need for oral medication overlap. Why each distractor fails: - B. **Invega Sustenna** does not require oral overlap when started with proper Day 1 and Day 8 deltoid loading doses. - C. 3-monthly paliperidone (**Invega Trinza**) can only be initiated after a patient has been stabilized on once-monthly **Invega Sustenna** for at least 4 months. - D. Biweekly gluteal injections with 4 weeks of oral overlap describes the protocol for **Risperdal Consta**, not **Invega Sustenna**. Test-taking pearl: **Invega Sustenna** initiation requires Day 1 (150 mg) and Day 8 (100 mg) deltoid loading doses without oral overlap. Concept tested: Dosing protocol for paliperidone palmitate initiation. Best Next Step. Best next step. Move to the next parent section under FITZGERALD CH02 covering Special populations and practice settings called out in this chapter to master pediatric, geriatric, pregnant, and correctional mental health care standards for board certification. Next. Topic. STOPP Criteria: Physiologic system organization for rational prescribing. Bottom Line. Bottom line. The **STOPP** (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) criteria provide an explicit, evidence-based screening framework organized by **physiologic organ systems** to identify potentially inappropriate medications in adults aged 65 and older. By categorizing inappropriate drug risks according to organ systems (such as Central Nervous System, Cardiovascular, Respiratory, and Gastrointestinal), **STOPP** helps clinicians identify drug-disease interactions, duplicate therapies, and fall-inducing medications, overcoming key limitations of standalone drug lists to promote rational prescribing and deprescribing. Key Concepts on STOPP Criteria and Rational Prescribing. * Physiologic System Organization: Unlike traditional drug lists, the **STOPP** criteria organize potentially inappropriate medications by **physiologic organ systems**. This allows the PMHNP to systematically evaluate drug toxicity in the context of specific organ dysfunction, such as renal clearance impairment, cardiac conduction deficits, or central nervous system frailty. * Purpose and Target Population: Designed for adults aged 65 and older across ambulatory, acute, and long-term care settings. The primary goal is reducing adverse drug events, hospitalizations, polypharmacy, and healthcare costs. * Complementary Dual Framework (STOPP / START): * **STOPP** (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions): Focuses on identifying and stopping inappropriate, unnecessary, or hazardous medications. * **START** (Screening Tool to Alert to Right Treatment): Focuses on identifying prescribing omissions, flagging evidence-based, essential medications that should be initiated for specific clinical conditions. * High-Yield Psychiatric STOPP Rules for Older Adults: * Central Nervous System: Avoid long-term **benzodiazepines** and Z-drug hypnotics (**zolpidem**, **eszopiclone**) due to increased risks of delirium, cognitive impairment, ataxia, falls, fractures, and motor vehicle accidents. * Anticholinergic Load: Avoid highly anticholinergic tricyclic antidepressants (**amitriptyline**, **clomipramine**, **doxepin** over 6 mg daily, **imipramine**) due to risks of delirium, confusion, urinary retention, severe constipation, and orthostatic hypotension. * Antipsychotic Safety: Avoid first- and second-generation antipsychotics for behavioral symptoms of dementia or delirium unless non-pharmacological interventions have failed and the patient poses an immediate threat of serious harm to self or others, due to increased risks of stroke and mortality. * Antidepressants and Falls: Exercise caution or avoid **SSRIs**, **SNRIs**, and **TCAs** in patients with a history of recurrent falls or fractures. Safety Alert. Safety alert. Never continue central nervous system sedatives, such as **benzodiazepines** or tertiary **tricyclic antidepressants**, in older adults without performing a systematic **STOPP** review. Age-related declines in hepatic metabolism (CYP450 enzyme activity) and renal clearance cause drug accumulation, turning routine doses into toxic triggers for acute delirium, severe gait instability, hip fractures, and fatal respiratory depression. Board Trap. Board trap. Do not assume that rational prescribing in geriatric psychiatry only means adding safer medications or adjusting doses. On board exams, test writers present complex older patients on multiple duplicating psychotropics and test whether you recognize the need for active deprescribing. Selecting a new medication to treat a side effect of an existing inappropriate drug (a prescribing cascade) is a major board trap. Use **STOPP** criteria to identify and discontinue the offending drug first. First-Line. First-line. Your **first-line** action when evaluating an older adult taking multiple medications who presents with new confusion, sedation, or fall history is performing a comprehensive medication reconciliation using the **STOPP** criteria, checking vital signs with orthostatic blood pressures, and systematically deprescribing potentially inappropriate medications before considering any new psychotropic initiation. Compare and Distinguish. STOPP Criteria vs. Beers Criteria. * Think STOPP Criteria when: Evaluating potentially inappropriate prescriptions organized systematically by **physiologic organ systems** (Central Nervous System, Cardiovascular, Gastrointestinal, Renal) to catch drug-disease and drug-class risks in older adults. * Think Beers Criteria when: Reviewing an explicit list published and updated by the American Geriatrics Society (AGS) that categorizes potentially inappropriate medications to avoid in most older adults, drugs to avoid with specific conditions, and drugs to use with caution. * Priority difference: **STOPP** uses a physiologic system organization that overcomes some limitations of **Beers** by directly linking drug toxicity to organ system pathology, while **Beers** provides a widely recognized standalone list of hazardous drugs. * What boards are testing: Recognizing complementary tools used in geriatric deprescribing to prevent adverse drug events. STOPP Criteria vs. START Criteria. * Think STOPP Criteria when: Identifying potentially inappropriate medications, duplicate therapies, or dangerous drug-disease interactions that should be discontinued or reduced in older adults. * Think START Criteria when: Identifying prescribing omissions, which are evidence-based, essential medications that should be initiated to treat specific untreated conditions in older adults. * Priority difference: **STOPP** focuses on stopping harmful or unnecessary medications, whereas **START** focuses on starting beneficial, omitted treatments. * What boards are testing: Differentiating deprescribing inappropriate drugs (**STOPP**) from adding indicated essential therapies (**START**). Next. Topic. Question 1 (Fitzgerald Sample Item). According to the recommendations found in the Beers Criteria and the STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) screening tools, which of the following medications should be avoided in frail older adults due to a high risk of anticholinergic adverse effects, orthostatic hypotension, and sedation? - A. **Sertraline** - B. **Amitriptyline** - C. **Buspirone** - D. **Donepezil** Pause. Answer. B. Why it is correct: **Amitriptyline** is a tertiary tricyclic antidepressant (TCA) with potent anticholinergic, antihistaminic, and alpha-1 adrenergic blocking properties. Both the Beers Criteria and **STOPP** criteria explicitly designate tertiary TCAs like **amitriptyline** as potentially inappropriate medications in older adults due to severe risks of delirium, confusion, urinary retention, constipation, sedation, orthostatic hypotension, and falls. Why each distractor fails: - A. **Sertraline** is an SSRI considered a preferred first-line antidepressant in older adults, though monitoring for hyponatremia is required. - C. **Buspirone** is an anxiolytic that does not cause cognitive impairment, anticholinergic toxicity, or motor ataxia in geriatric populations. - D. **Donepezil** is a cholinesterase inhibitor used to treat mild-to-moderate neurocognitive disorders, not a medication routinely flagged for avoidance unless severe bradycardia is present. Test-taking pearl: Both **STOPP** and Beers criteria flag tertiary TCAs like **amitriptyline** as high-risk medications to avoid in older adults due to anticholinergic toxicity and fall hazards. Concept tested: Potentially inappropriate prescribing in older adults using **STOPP** and Beers criteria. Live Board Practice Items. Question 2. A 76-year-old female with mild neurocognitive disorder and hypertension is brought to the clinic by her daughter. The PMHNP conducts a medication reconciliation and notes that the patient is taking **lorazepam** 1 mg twice daily for anxiety, **diphenhydramine** 50 mg at bedtime for sleep, **amitriptyline** 25 mg at bedtime for nerve pain, and **lisinopril** 10 mg daily. The patient has experienced two recent falls and increasing daytime confusion. Which tool organizes potentially inappropriate prescriptions by physiologic system to guide deprescribing for this patient? - A. **CRAFFT** screening tool - B. **STOPP** (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) criteria - C. **COWS** (Clinical Opioid Withdrawal Scale) - D. **AIMS** (Abnormal Involuntary Movement Scale) Pause. Answer. B. Why it is correct: The **STOPP** criteria organize potentially inappropriate medications by physiologic organ system (such as Central Nervous System, Cardiovascular, and Gastrointestinal systems) to help prescribers identify and discontinue risky medications in adults aged 65 and older. Why each distractor fails: - A. The **CRAFFT** tool screens for substance use in adolescents, not geriatric polypharmacy. - C. The **COWS** quantifies opioid withdrawal severity, not inappropriate geriatric prescribing. - D. The **AIMS** detects tardive dyskinesia from antipsychotics, not overall polypharmacy or inappropriate drug classes. Test-taking pearl: **STOPP** criteria organize inappropriate medications by physiologic system to streamline geriatric deprescribing. Concept tested: Indication and structure of **STOPP** criteria in geriatric assessment. Question 3. A PMHNP is reviewing the medication list of an 82-year-old male residing in an assisted living facility. The provider wishes to evaluate both potentially inappropriate prescriptions that should be stopped and potential prescribing omissions of evidence-based medications that should be started. Which paired screening framework fulfills this dual assessment role? - A. **AUDIT** and **CAGE** - B. **STOPP** and **START** criteria - C. **HAM-D** and **HAM-A** - D. **GDS** and **MMSE** Pause. Answer. B. Why it is correct: **STOPP** (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) identifies medications to discontinue, while **START** (Screening Tool to Alert to Right Treatment) identifies evidence-based medications that are clinically indicated but omitted, offering a comprehensive framework for rational geriatric prescribing. Why each distractor fails: - A. **AUDIT** and **CAGE** are screening tools for alcohol use disorders, not medication optimization tools. - C. **HAM-D** and **HAM-A** measure depression and anxiety symptom severity, not drug appropriateness. - D. **GDS** (Geriatric Depression Scale) and **MMSE** evaluate mood and cognition, not prescribing appropriateness or omissions. Test-taking pearl: Pair **STOPP** (stop inappropriate drugs) with **START** (start omitted beneficial drugs) for rational geriatric medication management. Concept tested: Comprehensive dual framework of **STOPP** and **START** criteria. Question 4. Which fundamental clinical advantage does the **STOPP** criteria offer compared to traditional drug-list tools like the **Beers** Criteria when managing older adults with multiple chronic medical conditions? - A. **STOPP** criteria provide exact pediatric dosing conversions for neurodevelopmental disorders. - B. **STOPP** criteria organize inappropriate prescribing rules by physiologic organ systems, capturing drug-disease and drug-class risks across complex medical comorbidities. - C. **STOPP** criteria eliminate the need for renal function monitoring in chronic kidney disease. - D. **STOPP** criteria mandate the use of third-generation antipsychotics for all geriatric insomnia cases. Pause. Answer. B. Why it is correct: The **STOPP** criteria structure prescribing warnings around physiologic organ systems (Central Nervous System, Cardiovascular, Respiratory, Renal), allowing clinicians to easily recognize how specific drug classes exacerbate underlying systemic medical illnesses. Why each distractor fails: - A. **STOPP** criteria specifically target older adults aged 65 and older, not pediatric populations. - C. **STOPP** criteria emphasize renal clearance and dosage adjustments, rather than eliminating renal monitoring. - D. Antipsychotics are not indicated or recommended for routine insomnia in older adults under **STOPP** or **Beers** guidelines. Test-taking pearl: **STOPP** criteria categorize inappropriate drugs by physiologic organ systems to match drug risks with systemic disease. Concept tested: Structural design and clinical utility of **STOPP** criteria. Best Next Step. Best next step. Move to the next leaf under Pharmacology Safety covering START Criteria: Screening Tool to Alert to Right Treatment for essential prescribing omissions in older adults to master complete geriatric medication optimization for board certification. Next. Topic. SSRI Black Box: Increased suicidality risk under age 25. Bottom Line. Bottom line. All antidepressant medications carry an FDA black box warning regarding an increased risk of suicidal thoughts, ideation, and behavior (suicidality) in children, adolescents, and young adults under age 25 (ages 18 to 24). This risk is highest during the first 1 to 4 weeks of initiating therapy or following dose titrations, driven by early physical energy surges before depressive mood shifts resolve. Notably, short-term trials showed an increase in suicidal ideation rather than completed suicides. Beyond age 24, antidepressant suicidality risk neutralizes, and in adults age 65 and older, antidepressants actually reduce suicide risk compared to placebo. Key Concepts on SSRI Black Box Warning and Suicidality Under Age 25. * FDA Black Box Warning Scope: Applies to all antidepressant classes (**SSRIs**, **SNRIs**, **TCAs**, **MAOIs**, **NDRIs**, **NaSSAs**) when prescribed to individuals under age 25 for depression or other psychiatric indications. * Age-Dependent Risk Profile: * Ages 0 to 24 (under age 25): Increased risk of suicidal ideation and behavior. * Ages 25 to 64: Neutral effect on suicide risk compared to placebo. * Ages 65 and older: Statistically significant reduction in suicide risk compared to placebo. * High-Risk Monitoring Window: The highest risk for suicidal ideation occurs during the first 1 to 4 weeks of initiating antidepressant therapy or following an upward dose titration. As motor retardation lifts before mood improves, patients gain physical energy to act on pre-existing suicidal impulses. * Behavioral Activation and Akathisia: Early serotonin activation can manifest as severe restlessness, agitation, insomnia, irritability, or anxiety, which must be distinguished from worsening depression or emergent bipolar mania. * FDA-Approved SSRIs in Pediatric/Adolescent Major Depressive Disorder: * **Fluoxetine** (**Prozac**): FDA-approved for MDD in children and adolescents aged 8 and older. * **Escitalopram** (**Lexapro**): FDA-approved for MDD in adolescents aged 12 to 17. * **Sertraline** (**Zoloft**): FDA-approved for pediatric OCD (aged 6 and older), but not FDA-approved for pediatric MDD (though widely used off-label). * Prescriber Responsibilities and Documentation: Prescribers must inform patients and parents/caregivers about the black box warning, distribute FDA medication guides, establish frequent face-to-face monitoring during early treatment weeks, create a safety plan, and document the risk-benefit analysis thoroughly in the clinical record. Safety Alert. Safety alert. Never discontinue or hold an **SSRI** without performing a suicide risk assessment when a young adult or adolescent experiences mild initial activation or anxiety. Untreated major depression carries a far higher risk of completed suicide than antidepressant therapy. Educate families to report sudden behavioral shifts, severe agitation, or new suicidal thoughts immediately, and schedule weekly follow-up contacts during the first month of treatment. Board Trap. Board trap. Do not select "discontinue the antidepressant" or "switch to a tricyclic antidepressant" when a question stem describes a 20-year-old with major depression who reports mild restlessness or a subtle increase in passive suicidal thoughts two weeks after starting **fluoxetine**. Test writers want to see if you panic or recognize that early activation is expected. TCAs are far more dangerous due to lethal cardiac overdose risks. The correct board action is conducting a detailed suicide risk assessment, reinforcing safety planning, and monitoring closely rather than prematurely stopping effective therapy. First-Line. First-line. Your **first-line** intervention when prescribing an **SSRI** to a patient under age 25 is providing comprehensive psychoeducation to the patient and family regarding the black box warning, establishing a written safety plan, ordering an evidence-based first-line agent like **fluoxetine** or **escitalopram**, and scheduling close face-to-face or clinical follow-up during the initial 1 to 4 weeks of therapy. Compare and Distinguish. SSRI Black Box Warning in Youth vs. Geriatric Antidepressant Response. * Think Youth Under Age 25 when: Increased risk of suicidal ideation and behavioral activation occurs during initial dosing, requiring close family observation, safety planning, and frequent monitoring. * Think Geriatric Adults Age 65 and Older when: Antidepressant therapy significantly reduces suicide risk compared to placebo, though clinicians must monitor for hyponatremia (SIADH), orthostatic hypotension, and fall hazards. * Priority difference: In youth, monitor closely for paradoxical suicidal activation; in geriatrics, monitor for metabolic, cognitive, and cardiovascular side effects. * What boards are testing: Recognizing age-dependent variation in antidepressant suicide risk profiles across the lifespan. Fluoxetine vs. Escitalopram in Adolescent Depression. * Think Fluoxetine when: Treating major depressive disorder in children and adolescents aged 8 and older. Its long half-life minimizes discontinuation syndrome if doses are missed. * Think Escitalopram when: Treating major depressive disorder in adolescents aged 12 to 17. It offers low CYP450 drug interaction risks. * Priority difference: **Fluoxetine** is FDA-approved down to age 8 for MDD, whereas **escitalopram** is FDA-approved down to age 12 for MDD. * What boards are testing: Knowing exact age thresholds for FDA-approved pediatric depression treatments. Next. Topic. Question 1 (Fitzgerald Sample Item). A 14-year-old female meets criteria for a major depressive disorder. Which of the following is true regarding depression treatment in children and adolescents? - A. **Fluoxetine** is one of only two medications FDA approved for use with adolescents for major depressive disorder. - B. Children require lower doses of antidepressants than adults due to slower metabolism. - C. Psychopharmacology is more effective than psychotherapy in pediatric populations. - D. Tricyclic antidepressants offer a reasonable second line option for pediatric depression. Pause. Answer. A. Why it is correct: **Fluoxetine** (**Prozac**) and **escitalopram** (**Lexapro**) are the only two antidepressants with FDA approval for treating major depressive disorder in adolescents. **Fluoxetine** is approved for ages 8 and older, while **escitalopram** is approved for ages 12 and older. Why each distractor fails: - B. Children often have faster hepatic metabolism and higher renal clearance per kilogram, sometimes requiring adult-equivalent doses rather than lower doses. - C. Combination therapy (psychotherapy plus pharmacotherapy) or psychotherapy alone is preferred initial treatment; medication alone is not superior. - D. Tricyclic antidepressants (TCAs) lack demonstrated efficacy in pediatric depression studies and carry high risks of lethal cardiac toxicity and sudden death in overdose. Test-taking pearl: Remember that **fluoxetine** (age 8+) and **escitalopram** (age 12+) are the only FDA-approved antidepressants for adolescent major depressive disorder. Concept tested: FDA-approved antidepressants in pediatric and adolescent populations. Live Board Practice Items. Question 2. A 19-year-old college student with major depressive disorder is prescribed **sertraline** 50 mg daily. During a 2-week follow-up visit, he reports feeling "more restless and edgy," but denies active suicidal intent or plan. His parents express fear after reading the black box warning on the prescription bottle. How should the PMHNP advise the patient and family? - A. Discontinue **sertraline** immediately and initiate **amitriptyline**. - B. Reassure the family that the black box warning highlights an increased risk of suicidal ideation under age 25, validate that mild early activation can occur, reinforce the safety plan, and schedule close follow-up. - C. Stop the antidepressant and inform them that psychotropics are contraindicated under age 25. - D. Add **alprazolam** 1 mg three times daily to suppress activation permanently. Pause. Answer. B. Why it is correct: The black box warning alerts clinicians and families to increased suicidal thoughts and behavior in patients under 25, especially during initial treatment weeks. Reassuring the family, explaining early activation, reinforcing safety planning, and monitoring closely is the correct standard of care. Why each distractor fails: - A. TCAs like **amitriptyline** carry severe cardiac toxicity in overdose and are inappropriate alternatives. - C. Antidepressants are not contraindicated in young adults; untreated depression carries a far higher risk of completed suicide. - D. Long-term high-dose benzodiazepines pose severe dependence and disinhibition hazards in young adults. Test-taking pearl: Manage early SSRI activation with education, safety planning, and close follow-up rather than abrupt discontinuation. Concept tested: Clinical management of the SSRI black box warning in young adults. Question 3. Which age group experiences a statistically significant reduction in suicide risk when treated with antidepressant medications compared to placebo? - A. Children under age 12 - B. Adolescents aged 12 to 17 - C. Young adults aged 18 to 24 - D. Adults aged 65 and older Pause. Answer. D. Why it is correct: Extensive FDA meta-analyses demonstrate that while antidepressant suicidality risk is elevated under age 25 and neutral in middle-aged adults, it is significantly reduced in adults aged 65 and older compared to placebo. Why each distractor fails: - A. Children under 12 have an increased risk of suicidal ideation on antidepressants. - B. Adolescents aged 12 to 17 have an increased risk of suicidal ideation on antidepressants. - C. Young adults aged 18 to 24 represent the upper age limit of the FDA black box warning for increased suicidality. Test-taking pearl: Antidepressant suicide risk varies by age: increased under 25, neutral 25 to 64, and protective in ages 65+. Concept tested: Lifespan variation in antidepressant suicidality risk. Question 4. A PMHNP is evaluating a 16-year-old male with moderate major depressive disorder who has not responded to 8 weeks of individual cognitive behavioral therapy. Which SSRI is FDA-approved for initiating depression treatment in this patient? - A. **Paroxetine** - B. **Escitalopram** - C. **Fluvoxamine** - D. **Vortioxetine** Pause. Answer. B. Why it is correct: **Escitalopram** is FDA-approved for the treatment of major depressive disorder in adolescents aged 12 to 17 years (**fluoxetine** is also approved for ages 8 and older). Why each distractor fails: - A. **Paroxetine** is not FDA-approved for pediatric depression and carries high risks of discontinuation syndrome and activation. - C. **Fluvoxamine** is FDA-approved for pediatric OCD, but not for pediatric major depressive disorder. - D. **Vortioxetine** is a multimodal antidepressant approved only for adults aged 18 and older. Test-taking pearl: Only **fluoxetine** and **escitalopram** hold FDA indications for major depressive disorder in adolescents. Concept tested: FDA-approved pediatric psychopharmacology. Question 5. What is the underlying clinical rationale for the peak in suicidal ideation observed during the first 1 to 4 weeks of starting antidepressant therapy in young adults? - A. Antidepressants cause immediate severe hepatic toxicity that triggers delirium. - B. Physical energy and psychomotor retardation improve before depressed mood and cognitive hopelessness resolve, giving patients the energy to act on suicidal thoughts. - C. SSRIs completely block dopamine receptors in the nucleus accumbens within 24 hours. - D. Antidepressants cause rapid irreversible bone marrow suppression. Pause. Answer. B. Why it is correct: Early in antidepressant therapy (weeks 1 to 4), physical psychomotor retardation and fatigue often improve before the patient's depressed mood, cognitive despair, and hopelessness lift. This surge in physical energy enables the patient to organize and execute suicidal ideation. Why each distractor fails: - A. SSRIs do not cause acute hepatic delirium as a primary mechanism for suicidality. - C. SSRIs selectively inhibit serotonin reuptake, not dopamine receptor blockade in reward centers. - D. SSRIs do not cause acute bone marrow suppression; agranulocytosis is associated with **clozapine**. Test-taking pearl: The suicide risk window occurs when physical energy returns before mood and hopelessness improve. Concept tested: Pathophysiology and timing of antidepressant-induced suicidality. Best Next Step. Best next step. Move to the next parent section under FITZGERALD CH02 covering Special populations and practice settings called out in this chapter to master pediatric, geriatric, pregnant, and correctional mental health topics for board certification. Next. New section. Practice Favorites. Topic. No-Harm Contracts: No evidence of utility; do not use. Bottom Line. Bottom line. Traditional **no-harm contracts**, also called **contracts for safety**, have no evidence of clinical utility or efficacy in preventing suicide or self-injurious behavior. Research demonstrates that written or verbal agreements where a patient promises not to harm themselves fail to reduce suicide attempts or suicide deaths, offer zero medicolegal protection for the clinician, and can create a false sense of security. Modern standards of care mandate replacing no-harm contracts with evidence-based **collaborative safety planning**, such as the Stanley-Brown Safety Planning Intervention, and formal **crisis response planning**. Key Concepts on No-Harm Contracts vs. Safety Planning. * Lack of Clinical Efficacy: Extensive research shows no reduction in suicidal ideation, suicide attempts, or completed suicides from using no-harm contracts. * Medicolegal Vulnerability: A signed no-harm contract does not protect a clinician from malpractice liability if a patient dies by suicide. Relying on a contract in place of thorough suicide risk assessment, environmental safety measures, or appropriate level of care constitutes a breach in the standard of care. * False Sense of Security: Prescribers may falsely assume a patient is safe simply because they signed an agreement. This can lead to superficial risk assessments, inadequate supervision, or premature discharge from emergency or inpatient settings. * Evidence-Based Alternative (Stanley-Brown Safety Plan): Rather than focusing on what a patient promises NOT to do, a **collaborative safety plan** is a prioritized, written list of coping strategies, internal distractions, social supports, professional emergency contacts (**988 Lifeline**), and **lethal means restriction** co-created with the patient for use during an acute crisis. Safety Alert. Safety alert. Never rely on a **no-harm contract** to manage a patient with active suicidal ideation, agitation, psychosis, severe depression, or acute substance intoxication. Relying on a contract for safety in place of immediate physical protection, lethal means restriction, continuous monitoring, or emergency hospitalization exposes the patient to high mortality risks and represents a severe breach of clinical safety standards. Board Trap. Board trap. Do not select "negotiate a no-harm contract" or "have the patient sign a contract for safety" when a board scenario asks for the most appropriate management plan for a suicidal patient. Test writers frequently include "contracting for safety" as a tempting distractor because it was historically common in clinical practice. On board exams, the correct answer is always implementing a written **collaborative safety plan**, removing lethal means, or placing the patient in an appropriate level of care. First-Line. First-line. Your **first-line** intervention for managing an outpatient presenting with suicidal ideation who is deemed safe for community care is co-creating a personalized, written **collaborative safety plan** that includes identifying warning signs, internal coping mechanisms, social distractions, emergency contacts, professional crisis resources (**988 Lifeline**), and **lethal means restriction**. Compare and Distinguish. No-Harm Contract vs. Collaborative Safety Plan. * Think No-Harm Contract when: An outdated agreement asking the patient to promise what they will NOT do, which lacks scientific evidence, offers no legal defense, and is strictly advised against by clinical guidelines. * Think Collaborative Safety Plan when: An evidence-based, structured, written intervention developed jointly with the patient that outlines actionable steps they WILL take during a crisis, including internal coping skills, social connections, professional crisis contacts, and restricting access to lethal means. * Priority difference: No-harm contracts focus defensively on patient promises, whereas safety plans provide practical, step-by-step crisis coping tools. * What boards are testing: Rejecting outdated safety contracts in favor of evidence-based safety planning interventions. Safety Planning Intervention vs. Involuntary Hospitalization. * Think Safety Planning Intervention when: A patient presents with suicidal ideation but demonstrates intact impulse control, active engagement, protective factors, and a clear commitment to utilize a written crisis response plan in the community. * Think Involuntary Hospitalization when: A patient presents with acute, imminent suicide risk, active plan and intent, severe agitation, active psychosis, severe substance intoxication, or complete inability to participate in safety planning. * Priority difference: Safety planning is appropriate for outpatient stabilization when imminent risk is absent, whereas involuntary commitment is mandated when clear and imminent danger to self requires acute physical containment in the least restrictive environment. * What boards are testing: Matching the level of clinical risk to the appropriate placement and safety intervention. Next. End of this drive.